# Parsaclisib

Source: https://onco.cc/drugs/parsaclisib/  
OnCo record `parsaclisib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Parsaclisib is an oral pi3k inhibitor from Incyte Corporation, in registered phase 2 trials for diffuse large B-cell lymphoma.

## Summary

Parsaclisib is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Incyte Corporation and Incyte Biosciences Japan GK, in diffuse large B-cell lymphoma. A phosphoinositide 3-kinase inhibitor: the name stem -lisib marks a small molecule that blocks PI3K signalling. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Also known as: INCB050465
- Tags: pipeline; ctgov-ingest; registry-only
- Modality: Oral PI3K inhibitor
- Mechanism: A phosphoinositide 3-kinase inhibitor: the name stem -lisib marks a small molecule that blocks PI3K signalling.

## Sources

- ClinicalTrials.gov: trials of Parsaclisib: https://clinicaltrials.gov/search?intr=Parsaclisib

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- companies: [Incyte](https://onco.cc/companies/incyte/)
- trials: [Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)](https://onco.cc/trials/nct04509700/), [To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL](https://onco.cc/trials/nct04661007/)

---
JSON: https://onco.cc/api/v1/entities/parsaclisib.json